<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419325</url>
  </required_header>
  <id_info>
    <org_study_id>A4070417</org_study_id>
    <secondary_id>2U54MD007600-31</secondary_id>
    <nct_id>NCT03419325</nct_id>
  </id_info>
  <brief_title>A Genomic Approach for Clopidogrel in Caribbean Hispanics</brief_title>
  <official_title>Adopting a Precision Medicine Paradigm in Puerto Rico: Leveraging Ancestral Diversity to Identify Predictors of Clopidogrel Response in Caribbean Hispanics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Puerto Rico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Puerto Rico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with
      cardiovascular disease, particularly those undergoing heart catheterization and stroke. A
      substantial amount of medical evidence has proven that patients with stroke or heart diseases
      can benefit from this medicine. However, significant variability in such expected benefits
      has been found among individuals receiving Clopidogrel, with some patients not having the
      benefit of reduced complications and adverse cardiovascular events. Prior studies have
      demonstrated a significant association between certain variants on patient's genes (e.g.,
      CYP2C19) and poor response to Clopidogrel and, therefore, major adverse cardiovascular
      events. Variation in other genes and other factors such as platelet activation, weight,
      diabetes mellitus (a medical condition that produces high blood sugar), concomitant use of
      other drugs and smoking status have also been proposed to be related with the same adverse
      outcomes. In this study the investigators would like to determine a possible association
      between these genes and the response to the medication among Caribbean Hispanic
      cardiovascular patients on Clopidogrel. In other population, it is known that patients with
      certain genetic variants have lower or magnified response to this medication when compared to
      those individuals taking the same dose and not carrying the genetic variations. However, a
      fundamental gap remains in understanding whether the genomic diversity of Caribbean Hispanics
      accounts for the observed high inter-individual variability of clinical outcomes to
      preventive dual antiplatelet therapy (DAPT) with Clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the substantial work in cardiovascular pharmacogenomics published over the past
      decade, a fundamental gap remains in understanding whether the genomic diversity of Caribbean
      Hispanics accounts for high inter-individual variability of clinical outcomes to preventive
      dual antiplatelet therapy (DAPT) with Clopidogrel. Caribbean Hispanics are disproportionately
      affected by cardio-metabolic disorders, but with a limited expectation of benefits from
      existing genomic-based algorithms. The investigators will focus on Clopidogrel to develop
      urgently-needed genomic-driven prescription guidelines for this population. To this purpose,
      the investigators propose to perform the first ever genome-wide association study (GWAS) of a
      pharmacogenetically actionable prescription drug in Caribbean Hispanics. This proposal will
      also take a novel approach to definitively assess the admixture component and is also highly
      practical for the development of a clinical decision support (CDS) tool. The investigators
      will implement a treatment algorithm to guide DAPT in Caribbean Hispanics and will create a
      repository of genomic DNAs and fully annotated clinical and genomic dataset from Caribbean
      Hispanics with cardiovascular diseases. The investigators will test the following hypothesis:

      There are unknown genetic variants that uniquely contribute to Clopidogrel responsiveness in
      Caribbean Hispanics to such extent that a developed CDS tool that incorporates personal
      ethno-specific genotypes and ex vivo pharmacodynamics (PD) testing will help enable more
      precise recommendations for optimizing medical outcomes to antiplatelet therapy in this
      population. This hypothesis will be tested with the following specific aims:

      1) To conduct a Genome-Wide Association Study (GWAS) of residual on-treatment platelet
      reactivity in Clopidogrel-treated Caribbean Hispanic patients of Puerto Rico. 2) To implement
      a treatment algorithm based on ex vivo PD and genetic test results to guide DAPT in Caribbean
      Hispanics. 3) To create a repository of biological specimens and fully annotated clinical and
      genomic dataset (relevant genotypes and phenotypes) from Caribbean Hispanics with
      cardiovascular diseases.

      The study will be conducted over 5 years in 1,000 cardiovascular patients treated with
      Clopidogrel for secondary prevention of thromboembolic events. It is expected that this study
      advances the adoption of a Precision Medicine (PM) paradigm for the benefit of Hispanic
      patients. The richer genetic variance in Latinos is likely to contribute substantially to
      variability in response to drug treatments, a component that will be missed by traditional
      studies in homogeneous populations. This addressable oversight is of great concern, since it
      will tend to exacerbate the healthcare disparity already experienced by Hispanic populations
      in the US. Hispanics have been largely excluded from Precision Medicine initiatives, which
      increase dramatically the disparities in translating benefits from new findings in
      pharmacogenomics to this medically underserved population, exacerbating the existing inequity
      in healthcare services. Accordingly, the proposed research will expand current understanding
      on the pharmacogenomics of Clopidogrel. Advancing knowledge in the under-investigated area of
      pharmacogenetics in minority populations will generate results that apply to personalize DAPT
      in the wider population as it moves, inevitably, toward increasing heterogeneity through
      admixed genomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After being consented, patients will undergo rapid ex vivo platelet functional testing (i.e., residual platelet reactivity units, PRU, measured using the VerifyNow P2R12 assay for Clopidogrel response) and CYP2C19 genotyping. Patients will then be categorized into 4 groups based on tests results: 1) high on-treatment platelet reactivity (HTPR)/ CYP2C19 loss-of-function (LOF) alleles (i.e., presence of both HTPR and CYP2C19 LOF alleles); 2) HTPR/No-LOF (presence of HTPR, but no CYP2C19 LOF allele); 3) No-HTPR/LOF (presence of a CYP2C19 LOF allele, but no HTPR); 4) No-HTPR/No-LOF (absence of both HTPR and CYP2C19 LOF alleles).</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE) reductions</measure>
    <time_frame>six months after intervention</time_frame>
    <description>MACE reductions will be the composite of all-cause death, MI (according to the universal definition), stroke or coronary revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with treatment-related cardiovascular (CV) death</measure>
    <time_frame>six months after intervention</time_frame>
    <description>death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, CV procedures, CV hemorrhage and other CV causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with treatment-related stent thrombosis</measure>
    <time_frame>six months after intervention</time_frame>
    <description>definite or confirmed stent thrombosis as proposed by the Academic Research Consortium (ARC): i.e., symptoms suggestive of an acute coronary syndrome and angiographic or pathologic confirmation of stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>six months after intervention</time_frame>
    <description>as defined by Bleeding Academic Research Consortium (BARC) criteria</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cardiovascular Disease (CVD)</condition>
  <condition>Stroke</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>HTPR/LOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:
An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HTPR/no-LOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of HTPR, but no CYP2C19 LOF allele found:
An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no-HTPR/LOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Presence of a CYP2C19 LOF allele, but no HTPR:
An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-HTPR/No-LOF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Absence of both HTPR and CYP2C19 LOF alleles:
Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CYP2C19 test</intervention_name>
    <description>Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).</description>
    <arm_group_label>HTPR/LOF</arm_group_label>
    <arm_group_label>HTPR/no-LOF</arm_group_label>
    <arm_group_label>no-HTPR/LOF</arm_group_label>
    <arm_group_label>No-HTPR/No-LOF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>P2RY12 assay</intervention_name>
    <description>Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).</description>
    <arm_group_label>HTPR/LOF</arm_group_label>
    <arm_group_label>HTPR/no-LOF</arm_group_label>
    <arm_group_label>no-HTPR/LOF</arm_group_label>
    <arm_group_label>No-HTPR/No-LOF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caribbean Hispanics (Puerto Ricans, Dominicans or Cubans) residing in Puerto Rico,
             whose parents are also of Hispanic origin

          -  Both genders (Males/Females)

          -  Age â‰¥21

          -  Receiving Clopidogrel for therapeutic indications.

          -  No clinically active hepatic abnormality

          -  The ability to understand the requirements of the study

          -  The ability to comply with study procedures and protocol

          -  A female patient is eligible to enter the study if she is of child-bearing potential
             and not pregnant or nursing, or not of child-bearing potential

        Exclusion Criteria:

          -  Non-Hispanic patients (race/ethnicity is self-reported by the patients)

          -  Currently enrolled in another active research protocols at the participating
             institutions

          -  BUN &gt;30

          -  Creatinine &gt;2.0 mg/dL

          -  Platelet count &lt;100,000/mm3

          -  Nasogastric or enteral feedings

          -  Acute illness (e.g., sepsis, infection, anemia)

          -  HIV/AIDS, Hepatitis B patients

          -  Alcoholism and drug abuse

          -  Patients with any cognitive and mental health impairment

          -  Sickle cell patients

          -  Active malignancy

          -  Patients taking another antiplatelet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Duconge, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puerto Rico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge Duconge, PhD</last_name>
    <phone>(787) 758-2525</phone>
    <phone_ext>5312</phone_ext>
    <email>jorge.duconge@upr.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyle Melin, PharmD</last_name>
    <phone>(787) 758-2525</phone>
    <phone_ext>3711</phone_ext>
    <email>kyle.melin@upr.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital at Carolina</name>
      <address>
        <city>Carolina</city>
        <zip>00984</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Lopez-Candales, MD</last_name>
      <email>candales33@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Hospital of Puerto Rico and the Caribbean</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar F Hernandez-Suarez, MD</last_name>
      <email>dagmar.hernandez@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Puerto Rico</investigator_affiliation>
    <investigator_full_name>Jorge Duconge</investigator_full_name>
    <investigator_title>Proffesor, PhD</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary interventions (PCI)</keyword>
  <keyword>secondary stroke prevention</keyword>
  <keyword>dual antiplatelet therapy (DAPT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

